Traveling Exhibit of Cancer Educational Resources

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 6
Volume 6
Issue 6

ROCHESTER, NY--The WHO International Network for Cancer Education (INCE) has joined with its first partner, the American Association for Cancer Education (AACE), to put together an international traveling exhibit of educational materials and resources for cancer education, to be shown at many of the smaller cancer congresses around the world, Charles D. Sherman, Jr., MD, told Oncology News International.

ROCHESTER, NY--The WHO International Network for Cancer Education (INCE)has joined with its first partner, the American Association for CancerEducation (AACE), to put together an international traveling exhibit ofeducational materials and resources for cancer education, to be shown atmany of the smaller cancer congresses around the world, Charles D. Sherman,Jr., MD, told Oncology News International.

Dr. Sherman is director of the Highland Hospital Cancer Treatment Center,Rochester, NY, and co-director of INCE, along with Richard R. Love, MD,of the University of Wisconsin, Madison.

The INCE expects the initial collection to be exhibited at the AACEmeeting in Atlanta next October; it then will be reviewed and refined fordisplay elsewhere. An offshoot of this project is the production of anInternational Directory of materials and resources for cancer education,as well as individuals and organizations involved in cancer education.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.